FDA Announces Approval of Guidance for Reporting Adverse Events During Influenza Pandemic

Summary

The Food and Drug Administration (FDA) has received approval from the Office of Management and Budget (OMB) to collect information on postmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemic, as mandated by the Paperwork Reduction Act of 1995.